EscharEx clinical trials
EscharEx is named as an intervention in 3 current clinical trials in our USA, Poland, Germany, Spain, Italy, Austria, Canada and Israel registers. 2 are recruiting patients now. The most common phase is Phase 1/2. The lead sponsor is MediWound Ltd. The most-studied condition is Superficial Basal Cell Carcinoma. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
How EscharEx works
All drug targets →- BurnPhase 3
- Diabetic footPhase 2
- Diabetic retinopathyPhase 2
- Varicose ulcerPhase 2
- Basal cell carcinomaPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4298054, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for EscharEx
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of EscharEx
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
NCT06568627 · Venous Leg Ulcer (VLU)
|
Phase 3 | Recruiting | MediWound Ltd | USA, Germany, Spain, Italy, Poland, Austria, Canada, Israel |
|
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
NCT05157763 · Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
|
Phase 1/2 | Recruiting | MediWound Ltd | USA |
|
Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)
NCT06690177 · Venus Leg Ulcers
|
Phase 2 | Not yet open | MediWound Ltd | USA, Poland |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
EscharEx in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing EscharEx. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A multicenter, prospective, randomized, placebo and non-surgical standard of care (NSSOC) controlled study, performed to evaluate the safety and efficacy of EscharEx and its placebo (gel vehicle) compared to NSSOC in participants with Venous Leg Ulcers (VLU)
2026-526070-16-00 · Skin and Connective Tissue Diseases
|
Phase 2 | Authorised | Mediwound Ltd | Czechia, Slovakia |
Conditions studied with EscharEx
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| MediWound Ltd | 3 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Questions about EscharEx trials
How many clinical trials are testing EscharEx?
3 current trials in our USA, Poland, Germany, Spain, Italy, Austria, Canada and Israel registers name EscharEx (also registered as EX-02) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are EscharEx trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 2 with sites in USA, 1 with sites in Poland, 1 with sites in Germany, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Austria, 1 with sites in Canada and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors EscharEx clinical trials?
The lead sponsor is MediWound Ltd. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how EscharEx works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how EscharEx works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists EscharEx (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.